A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies

BACKGROUND: The economic burden of interstitial lung disease (ILD) is unknown, limiting informed resource allocation and planning. We sought to conduct the first systematic review on the direct, indirect, and overall costs associated with ILD and to evaluate the cost-effectiveness of current therapi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Alyson W., Koo, John, Ryerson, Christopher J., Sadatsafavi, Mohsen, Chen, Wenjia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020025/
https://www.ncbi.nlm.nih.gov/pubmed/35443657
http://dx.doi.org/10.1186/s12890-022-01922-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020025/
https://www.ncbi.nlm.nih.gov/pubmed/35443657
http://dx.doi.org/10.1186/s12890-022-01922-2

Ejemplares similares